RFK Jr. Peptide Policy Explained: What HHS Changed for BPC-157 and Five Other Peptides

By the Astramide Research Team. Reviewed by the Chief Science Officer. Published October 30, 2026. Updated October 30, 2026. Status last verified October 30, 2026.

What did HHS announce on October 28, 2026?

HHS published a document titled "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (HHS policy, October 2026). The Federal Register notice of availability was filed on October 28, 2026 at 11:15 am and published on October 30, 2026 (Federal Register, 91 FR 68526). It is signed by Secretary Kennedy and issued by the Office of the Secretary.

Enforcement discretion means the agency states it does not intend to act against certain conduct that would otherwise fall outside the law. It is not a rule. The notice says the policy "does not establish any rights for any person and is not binding on HHS or the public." Section 503A of the Food, Drug, and Cosmetic Act covers patient-specific compounding by state-licensed pharmacies and physicians; our peptide glossary defines 503A, the bulks list and related terms.

Which six peptides does the HHS peptide policy cover?

Appendix A of the policy lists six peptide bulk drug substances: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500 (HHS policy, Appendix A). They are the six that the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend in July 2026, after FDA staff had recommended against all seven peptides on the agenda (DLA Piper, Jul 31, 2026).

Peptide	In Appendix A	PCAC vote, July 23 to 24, 2026
BPC-157	Yes	8 to 6, 1 abstention
KPV	Yes	8 to 6, 1 abstention
MOTS-c	Yes	8 to 6, 1 abstention
TB-500	Yes	8 to 6, 1 abstention
Semax	Yes	8 to 5
Epitalon	Yes	7 to 4
Emideltide (DSIP)	No	6 to 7, not recommended

Committee votes are advisory. Our explainer on whether peptides are legal in the US covers the meeting and the history before it.

Coverage is narrow. Each peptide must match the identity set out in Appendix B, which includes "amino acid sequence, chemical structure, molecular weight, and molecular formula," along with limits on route of administration. A law firm review notes the policy "does not extend to all forms of these peptides" (Frier Levitt, Oct 28, 2026).

Is BPC-157 FDA approved or legal now?

BPC-157 is not FDA approved, and the HHS policy does not change that. No FDA-approved drug contains BPC-157, and it has no USP monograph (DLA Piper, Jul 31, 2026). BPC-157 is also still not on the 503A bulks list.

What changed on October 28, 2026 is narrower. HHS says it will not take enforcement action against licensed 503A pharmacies, federal facilities and physicians that compound BPC-157 under all ten conditions below, including a patient-specific prescription. Research-use-only BPC-157 sits outside the policy: HHS set no new rules for it, and the FDA's existing intended-use approach still applies. Research-use-only material is sold for laboratory research only and is not for human use.

Who does the HHS peptide policy apply to?

It applies to three groups: a "State-licensed pharmacy, Federal facility, or licensed physician" compounding under section 503A of the Food, Drug, and Cosmetic Act. Frier Levitt notes it "does not independently extend enforcement discretion to outsourcing facilities operating under Section 503B." State pharmacy board requirements still apply, and Jeff Cohen, co-founder of the American Peptide Association, told Reuters that states may not follow the federal approach (Reuters, Oct 28, 2026).

What conditions does the HHS peptide policy set for compounders?

HHS lists ten circumstances that must all be present. The table summarizes them from the policy text.

#	Condition	What the policy requires
1	Listed peptide	The bulk substance appears in Appendix A.
2	Identity	It matches the sequence, structure, molecular weight, formula and route limits in Appendix B.
3	Certificate of analysis	A valid COA covers identity, purity, potency and contaminants such as endotoxins, heavy metals, microbes and impurities.
4	Original manufacturer	Registered with the FDA under section 510, CGMP-compliant, facility location printed on the COA. A repacker or distributor alone does not qualify unless it validates the manufacturer and its COA.
5	Reporting	Products compounded, serious adverse events and quality issues go to the FDA (MedWatch) and the relevant states.
6	Label statement	"This is a compounded drug product. Not for resale."
7	Single ingredient	Only one Appendix A peptide per product. Blends fall outside the policy.
8	Oral forms	Documented oral bioavailability for the specific formulation.
9	Delivery devices	Only the one FDA 510(k)-cleared device type named in the policy may be co-packaged. More complex delivery devices are excluded.
10	Other law	All other FD&C Act requirements, including sanitary conditions and the patient-specific prescription requirement.

HHS explains the single-ingredient rule this way: "It will be easier to attribute adverse events or clinical outcomes to a specific substance" when each product holds one active ingredient (HHS policy).

What changed on October 28, and what did not?

The policy changes one thing: HHS's enforcement stance toward 503A compounding of six listed peptides. The table compares the position before and after the policy was filed.

Topic	Before October 28, 2026	After October 28, 2026
Compounding the six peptides under 503A	Not eligible: not on the 503A bulks list, no USP monograph, not in an approved drug	HHS says it will not take enforcement action when all ten conditions are met
FDA approval	None of the six is FDA approved	Unchanged
503A bulks list	Not listed	Still not listed; future rulemaking "may propose adding some or all"
503B outsourcing facilities	Not covered	Still not covered
Multi-peptide products	Not eligible	Outside the policy: one active ingredient per product
GHK-Cu, LL-37, Dihexa, Melanotan II, PEG-MGF	Awaiting a second advisory meeting	Unchanged; not in Appendix A
Research-use-only sales	FDA judges intended use from website content	Unchanged; the policy sets no new rules for them

The notice states that "Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed." On the bulks list, the Federal Register notice says "FDA's future rulemakings may propose adding some or all of these peptides to the 503A bulks list based on the available evidence" (Federal Register notice). A second advisory committee meeting on GHK-Cu, LL-37, Dihexa, Melanotan II and PEG-MGF is expected by the end of February 2027 (Holland & Knight, Oct 16, 2026).

What does the HHS peptide policy say about research-use-only peptides?

One sentence addresses them directly: "The Secretary of HHS has determined that this limited enforcement-discretion policy will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients" (HHS policy).

The policy does not create new rules for research suppliers. The FDA's existing approach still applies: in an August 24, 2026 warning letter, the FDA held that website content established intended human use despite "research use only" labeling (FDA warning letter, Aug 24, 2026). Our research use only policy sets out how Astramide sells.

Did FDA scientists agree with the HHS peptide policy?

No. According to Frier Levitt, HHS acknowledges that the FDA's Center for Drug Evaluation and Research "had recommended against listing the identified peptides, while PCAC voted in favor of their inclusion." The committee's July votes were close: four of the six passed 8 to 6 (see the vote table above). Reuters reported that several panel members had ties to peptide businesses or clinics, and that HHS said all cleared ethics checks (Reuters, Oct 28, 2026).

What happens next with the HHS peptide policy?

When	What to watch
October 30, 2026	Notice published in the Federal Register (91 FR 68526)
About November 13, 2026	Public comment window closes, two weeks after publication
By end of February 2027	Second PCAC meeting on five more peptides (expected; no date set)
12 to 24 months (estimate)	FDA rulemaking on the 503A bulks list
At any time	HHS may revisit the policy if a safety or quality issue arises

The policy applies "until a peptide bulk drug substance is addressed in a final rule as being included or not included on the 503A bulks list." No end date is given. Frier Levitt estimates that FDA rulemaking on the 503A bulks list may take 12 to 24 months (Frier Levitt, Oct 28, 2026). HHS may revisit the policy "if, among other things, a safety signal or product quality issue arises."

Written comments are open "until 2 weeks after date of publication in the Federal Register via regulations.gov on Docket No. HHS-OASH-2026-0496". Two weeks after the October 30 publication puts the close on or about November 13, 2026; regulations.gov shows the official date.

Batch verification standards: how do research buyers read a certificate of analysis?

For a laboratory, a certificate of analysis answers three questions: is the material what the label says, how pure is it, and what contaminants were tested for. Our guide on how to read a peptide COA walks through each result line, and our peptide testing process page describes the methods. Lot records are published in the certificates of analysis library. Astramide materials are sold for laboratory research only and are not offered for compounding.

This content is prepared by the Astramide Science Team and reviewed by the Chief Science Officer, overseeing analytical quality assurance and third-party laboratory partnerships with a focus on HPLC-based purity verification and research-grade peptide compound validation. All research peptides sold by Astramide are intended strictly for laboratory research use only.

Update log

• October 30, 2026: Published. Covers the HHS policy filed October 28, 2026 and published in the Federal Register on October 30, 2026.

Sources

• HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (October 2026)
• Federal Register, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, 91 FR 68526, document 2026-22192 (October 30, 2026)
• Frier Levitt, HHS Peptide Compounding Enforcement Discretion Policy (Oct 28, 2026)
• Reuters via KFGO, US health department to allow temporary sale of some unapproved peptides (Oct 28, 2026)
• DLA Piper, FDA AdComm Recommends Adding Six Peptides to Bulk List (Jul 31, 2026)
• Holland & Knight, Peptides at a Crossroads (Oct 16, 2026)
• FDA warning letter to TXP Innovations LLC dba Tex Peptides (Aug 24, 2026)